Data on the health state utility values of Multiple Sclerosis (MS) health states have been described as sparse or of questionable methodological quality. This has led to uncertainty in assessing the effectiveness and cost-effectiveness of treatments for MS, and has hampered decision-making regarding the funding of MS interventions.
Introduction
Multiple Sclerosis (MS) is a chronic, disabling neurological disorder which can affect any system of the body. It is one of the commonest global causes of neurological disability in young and middleaged adults (1) (2), with a worldwide prevalence of approximately 33 per 100,000 population (3) .
Approximately 85% of people when first diagnosed with MS are diagnosed with relapsing-remitting MS (RRMS) (4) . Their disease course is characterised by episodes when they are well and episodes, known as relapses, when they experience an acute exacerbation of existing symptoms or new symptoms (5) (6) . MS and the relapses experienced have a profound impact on health-related quality of life (7) (3), commensurate with congestive heart failure, chronic obstructive pulmonary disease, Type II diabetes, and having experienced an acute myocardial infarction in the previous year (8) .
One of the ways in which health-related quality of life can be assessed is by considering the health state utility values (HSUVs) of different health states experienced by individuals with the condition of interest. HSUVs are used to assign a value to health states that may be experienced. These values are on a scale where one represents, or is equivalent to, full health and zero is considered equivalent to being dead. Values can also be negative, representing health states valued as worse than being dead (9) . Such HSUVs have specific relevance to health policy and health technology assessments, as they comprise the 'quality weight' in quality-adjusted life-years (QALYs) (9) (10) . QALYs are one of the key inputs in analyses of the effectiveness and cost-effectiveness of treatments, and are one of the main outcome measures used in funding decision-making, particularly in the UK, Europe, and publically funded health care systems (11) (12) (13) (14). HSUVs can have a major impact on results obtained from health technology appraisals (15) and yet, data on the HSUVs of MS health states have been described as sparse or of questionable methodological quality (16) . Systematic reviews of the costeffectiveness of treatments for MS have highlighted particular issues with the HSUVs available for MS (17) (18) (19) (20) , and a systematic review of MS HSUVs (16) identified inconsistencies and marked variability in the values reported. For example, higher HSUVs have been described for disease severity scores indicative of poorer health status (21) (22) and HSUV losses associated with MS relapse events have been reported as ranging from 0.029 (23) to 0.8 (24) (25) . This has led to uncertainty in assessing the effectiveness and cost-effectiveness of treatments for MS (26) (19) , and hampered decision-making regarding the funding of MS interventions (27) (28) (29). Therefore, the aim here was to estimate HSUVs for MS using data from a prospective, longitudinal, cohort study of people with MS by demographic and clinical characteristics, including valuation by disease severity and the characteristics of relapses.
Methods
The South West Impact of Multiple Sclerosis (SWIMS) project Data from the UK South West Impact of Multiple Sclerosis (SWIMS) project (30) were used for analysis. SWIMS is a longitudinal, prospective, cohort study of people with MS in Devon and Cornwall (South West England), with individuals followed-up six-monthly. Full details of the study methods have been reported elsewhere (30) . Data are collected on demographics and clinical characteristics, and on a range of patient-reported outcome measures. SWIMS commenced recruitment in August 2004, and data from all participants who had completed initial questionnaires at October 2012 were included in this analysis.
The study was approved in the UK by the Cornwall and Plymouth and South Devon Research Ethics Committees, and written informed consent obtained from all participants.
Measures

Demographic and clinical characteristics
Participants reported their age and gender, the type of MS they had (aided by descriptions and graphical representations similar to those used by Bamer et al. (31) and Lublin et al. (32) ) and the length of time since their diagnosis. Participant-reported data was supplemented, where available, with clinician-reported assessment of disease severity using the Expanded Disability Status Scale (EDSS) (33) scores, collected during routine clinic visits. These were matched with HSUV data if recorded within the same three-month window.
Participants reported relapse events for the prior six months, reporting if they had experienced a relapse, the number experienced, their length ('lasted about 48 hours', 'lasted up to 1 week', 'lasted up to 1 month', or 'lasted longer than 1 month'), whether they had been admitted to hospital as a result, and if the relapse had limited everyday activities. They were asked to give these details for up to four relapses in the six month period. (At recruitment, this information was reported for the previous 12 months).
Health state utility values
Participants completed both the EQ-5D-3L (34) (35) (36) and version 2 of the SF-36 (37) from which the SF-6D (38) can be derived. Participants completed both instruments at baseline and, thereafter, one of each measure every six months.
The EQ-5D-3L (34) (35) (36) is the most widely used generic preference-based measure for deriving HSUVs (39) . It is used internationally (there are currently 141 language versions), and has become increasingly commonplace in clinical trials and economic evaluations in the UK, given that it is the measure recommended by NICE in its reference case for health technology assessment submissions (11). The EQ-5D-3L descriptive system has five dimensions, each of which can be assigned at three levels. Its dimensions are Mobility, Self-care, Usual activities, Pain/Discomfort and Anxiety/Depression. The levels relate to the severity of problems on each of the dimensions; 1 represents 'no problems', 2 'some or moderate problems, and 3 'extreme problems/unable', with the exception of Mobility level 3 which is described as 'confined to bed'. Participants' responses to the descriptive system were assigned HSUVs based on time trade-off valuations from a representative sample of members of the UK general population (40) (41) . EQ-5D-3L HSUVs range from -0.594 (equivalent to being dead) to 1 (full health).
The internationally recognised SF-36, currently in its second version, includes 36 self-report questions regarding functional health and well-being (37). The descriptive system of the SF-6D (38) is based on 
Results
Description of the sample and data
Data from 1,441 people with MS were available, comprising 11,778 completed SWIMS questionnaires. Respondents provided a mean (sd) of 8 (4) questionnaires, with a range from one to 17. The demographic and clinical features of participants on recruitment to SWIMS are given in Table   1 .
Representativeness of the sample
Approximately 75% of those approached have taken part in the SWIMS study and response rates have been remarkably high (90% at 3.5 years follow-up (42) ). The sample, at recruitment, was demographically comparable to other UK samples of people with MS (42) (43) (although the percentage of respondents reporting a diagnosis of primary progressive MS was slightly higher: 19% as compared to 15%) (43) . For example, previous population surveys over the past 20 years have found mean ages of between 49.3 and 52.0 years (as compared to 50.7 years in the SWIMS sample), and male to female gender ratios ranging from 1:2.1 to 1:2.8 (as compared to 1:2.8 in the SWIMS sample) (44) (45) (46) (47) (48) (49) (50) . In addition, the relapse rate in the SWIMS sample (1.1 a year) was very similar to those estimated in prospective evaluations of relapses (0.5 to 1 a year) (51) . The demographic and clinical characteristics of the SWIMS participants were also comparable to those of individuals described in a recent paper documenting findings from a UK MS Register project. The 4,516 respondents had a mean (sd) age of 50.7 (11.2) years, the same as the SWIMS sample, a female: male ratio of 2.5, and were a mean (sd) of 10.9 (8.9) years since diagnosis (43) .
Health state utility values (HSUVs) 6,066 fully completed EQ-5D questionnaires were available from 1,406 participants, and 5,964 SF-6D responses were provided by 1,357 participants. The mean (sd) EQ-5D value was 0.563 (0.312), and the mean (sd) SF-6D value 0.620 (0.122). HSUVs for both measures covered the full valuation range.
A comparison of HSUVs for people with MS with UK norms is described in Supplement 1. Table 2 presents HSUVs by type of MS. According to both the EQ-5D and the SF-6D, HSUVs were lower for those with PPMS and SPMS than for those with RRMS, implying that the former sub-types of MS have a greater impact on health-related quality of life. Table 2 presents HSUVs for MS according to self-report time since diagnosis. When considering all types of MS, for both the EQ-5D and the SF-6D, values decrease from the point of diagnosis to 20 to 29 years post-diagnosis, followed by a slight increase between approximately 30 and 39 years, before a further decline thereafter. Although not so pronounced, this pattern also holds separately for individuals with RRMS. The trajectory for PPMS appears similar, but with HSUVs falling at 10 to 19 years, before improving at 20 to 29 years. Table 3 presents HSUVs by EDSS scores according to MS type. These data show a broadly linear decrease in values from EDSS 0 to EDSS 8. This is particularly apparent with the SF-6D data. With the EQ-5D, there is a flattening of values at EDSS 3 and EDSS 4, and a more sharp decrease from EDSS 7 to EDSS 8. There is greater variability in EQ-5D values of those individuals with RRMS. Their values were worse than individuals with PPMS at EDSS score 3 ('Moderate disability'), improved at EDSS score 4 ('Relatively severe disability'), dropped at EDSS 5 ('Disability precludes full daily activities'), and improved at EDSS 6 ('Assistance required to walk'). The trajectory of EQ-5D values by EDSS score was very similar for those who had PPMS and SPMS. Table 4 presents EQ-5D and SF-6D HSUVs for MS in the context of particular features of relapse events. These data show that experiencing a relapse in the previous six months (as compared to not experiencing a relapse) was associated with a decrement of 0.076 in EQ-5D value. The data also indicate that the number of relapses had a negative relationship with EQ-5D values. Individuals who experienced one relapse had a mean (sd) EQ-5D value of 0.570 (0.297), whilst those who experienced four relapses in the six month period had a mean (sd) EQ-5D value of 0.380 (0.377). The difference in EQ-5D values between those who had not experienced a relapse and those who had experienced four relapses was 0.23.
HSUVs by MS type
HSUVs by time since diagnosis
HSUVs by disease severity according to the EDSS
HSUVs in relation to relapses
These data also show that experiencing a relapse in the previous six months was associated with a mean decrement of 0.052 in SF-6D values. The number of relapses had a negative relationship with SF-6D values. Individuals who experienced one relapse had a mean (sd) SF-6D value of 0.607 (0.115), whilst those who experienced four relapses in the six month period had a mean (sd) SF-6D value of 0.551 (0.115). The difference in SF-6D values between those who had not experienced a relapse and those who had experienced four relapses was 0.098. The relationship between number of relapses and health state value decrement for the SF-6D was much less pronounced than for the EQ-5D.
The relationship between the length of relapses and HSUVs indicated that relapses that lasted 'about 48 hours' or for 'up to 1 week' were associated with the lowest EQ-5D and SF-6D values. Longer relapses were generally associated with higher HSUVs.
Relapses that limited everyday activities and, in particular, relapses that resulted in a hospital admission were associated with large decrements in HSUVs, as compared to those who did not experience a relapse. For example, the difference in EQ-5D values between those who did not have a relapse and those who had four relapses with the last resulting in a hospital admission was 0.275.
The equivalent figure for the SF-6D was 0.132.
Discussion
The An inconsistent result previously identified by Orme et al. (22) was replicated in the SWIMS data. In both studies, EQ-5D values were slightly higher when individuals had an EDSS score of 4 ('Relatively severe disability'), than when individuals had an EDSS score of 3 ('Moderate disability'). This finding was particularly apparent for SWIMS participants with RRMS (although this was based on a relatively small numbers of responses). In addition, this sub-group of individuals with RRMS had higher EQ-5D values at EDSS score 6 ('Assistance required to walk'), than at EDSS 5 ('Disability precludes full daily activities'). These findings may reflect complexities with how clinicians use the EDSS in practice, limitations with its psychometric properties, particular difficulties with rating the fluctuations in disability experienced by those with RRMS, the effect of patient coping strategies at the interfaces of EDSS 3/4 and 5/6, characteristics of the EQ-5D scoring at values of approximately 0.5 to 0.6, or the result may have occurred randomly. The relationship between HSUVs and EDSS scores warrants further investigation. This is also the first time that detailed data of this type have been presented for relapses according to their frequency, severity and length, and considering HSUVs alongside detailed information on the nature of relapses has provided new insights into the impact of differing forms of relapses on the health-related quality of life of people with MS. For example, relapses that lasted 'About 48 hours' or 'Up to 1 week' were associated with lower HSUVs than relapses that lasted 'Up to 1 month' or 'Longer than 1 month'. This may imply that shorter duration relapses are more severe in terms of their impact on health status. However, there is no clear evidence for this in the associated literature. Alternatively, this result might be a manifestation of the fact that shorter duration relapses are less likely to be treated, for example by a course of oral or intravenous steroids and, therefore, the effects linger and continue to impact on health status. But this is speculative, and the true explanation may relate to the known complexities of defining and categorising relapses. The data from SWIMS provides HSUVs for individuals with RRMS, PPMS and SPMS up to [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] years from diagnosis. This is a unique feature of the SWIMS dataset and such information has not previously been reported in this manner. The trajectory of the relationship between HSUVs and time since diagnosis may reflect some degree of adaptation to having MS (61) . Individuals with MS may view their health status as deteriorating over the first 20 to 29 years of having the disease. During this time they are likely to make adaptations to help live with the condition and develop psychological strategies for coping with the impact that it has on their lives. This process of adaptation, or 'normalisation', may then be reflected at 30 to 39 years from diagnosis by individuals perceiving their health status to be less severely affected, thus giving improved ratings on the EQ-5D and the SF-6D (SF-36). This process of adaptation may happen more quickly when the disease course is more rapid, which could explain the earlier increases in HSUVs for people with PPMS as compared to RRMS, although conclusions must be tentative as numbers providing HSUV data at 30 to 39 years from diagnosis were small for some types of MS.
The analyses reported here were limited by EDSS data not being available for all participants and not being reported concurrently with SWIMS data. Future research should aim to include EDSS assessments at the same data collection points as HSUVs. This said, problems with the EDSS, in both clinical and research practice (62) , suggest that an alternative measure of disease progression in MS may be long overdue. This is supported by the inconsistent relationship between EDSS and EQ-5D values at EDSS stages 3 and 4, and EDSS stages 5 and 6, found in this research and that of Orme et al. (22) . This research has illuminated some of the relative merits of two of the most commonly used generic preference-based measures (9) . Further research is now warranted to further investigate the psychometric functioning of the EQ-5D and the SF-6D for use in the context of MS.
The SWIMS data provide opportunities for further analyses using statistical techniques, and to develop hypotheses regarding the associations between health state utility values and the demographic and clinical features of people with MS. However, given the high quality data available, and the apparent representativeness of SWIMS participants, descriptive statistics are given in the present analyses to provide the data in a simple format for use and interpretation by others.
Regression-based analyses are a recommendation for future research.
The SWIMS dataset has very high response and retention rates and appears representative of the UK population of people with MS. As such, the current findings can be generalised to other people with MS. This work has demonstrated that MS has a major impact on the health-related quality of life as compared to population norms, especially as the disease progresses into its later stages and disability levels worsen. The findings also indicate the complexity of relationships between time since diagnosis and HSUVs, and specific features of relapses experienced and EQ-5D and SF-6D values. In addition, comparing the reported findings with those from previous studies has highlighted how different HSUVs can result based on the particular characteristics of the sample and the methodological approach taken. The SWIMS study has provided HSUV data based on specific clinical and demographic characteristics of people with MS. These can now be used to offer decision-makers more precise estimates of the effectiveness and cost-effectiveness of treatments for MS. * This category refers to instances where a respondent either ticked more than one type of MS ('benign', 'relapsing-remitting', 'primary progressive', 'secondary progressive') or ticked that they did not know which type they had. ** 3 people reported that they had experienced a relapse in the previous 12 months, but in answer to an additional question reported that that had had zero relapses in this time frame. [18] 40 [36] 64 [57] 30 [27] 25 [22] 19 [18] 61 [49] 270 [194] 0.897 (0.132) 0.763 (0.186) 0.719 (0.229) 0.523 (0.317) 0.596 (0.274) 0.438 (0.359) 0.502 (0.275) 0.623 (0.294) 21 [20] 23 [23] 46 [45] 17 [17] -11 [10] 
